|Home | About | Journals | Submit | Contact Us | Français|
Though multivitamins aim to prevent vitamin and mineral deficiency, there is a perception that multivitamins may prevent cardiovascular disease (CVD). Observational studies examining regular multivitamin use have been inconsistently associated with CVD, with no long-term clinical trials of multivitamin use.
To determine whether long-term multivitamin supplementation decreases the risk of major cardiovascular events among men.
The Physicians' Health Study II is a randomized, double-blind, placebo-controlled trial of a common daily multivitamin, that began in 1997 with continued treatment and follow-up through June 1, 2011.
A total of 14,641 male U.S. physicians initially aged ≥50 years (mean [± SD] age; 64.3 [± 9.2] years), including 754 men with a history of CVD at randomization, were enrolled.
Daily multivitamin, as Centrum Silver.
The primary cardiovascular outcome was a composite endpoint of major cardiovascular events, including nonfatal myocardial infarction (MI), nonfatal stroke, and fatal CVD. Secondary outcomes included MI and stroke individually.
During a median (interquartile range) follow-up of 11.2 (10.7 to 13.3) years, there were 1,732 confirmed major cardiovascular events. Compared with placebo, there was no significant effect of a daily multivitamin on major cardiovascular events (active and placebo multivitamin groups, 11.0 and 10.8 events per 1,000 person-years; hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.91–1.10; P=0.91). Further, a daily multivitamin had no effect on total MI (active and placebo multivitamin groups, 3.9 and 4.2 events per 1,000 person-years; HR, 0.93; 95% CI, 0.80–1.09; P=0.39), total stroke (active and placebo multivitamin groups, 4.1 and 3.9 events per 1,000 person-years; HR, 1.06; 95% CI, 0.91–1.23; P=0.48), or cardiovascular mortality (active and placebo multivitamin groups, 5.0 and 5.1 events per 1,000 person-years; HR, 0.95; 95% CI, 0.83–1.09; P=0.47). A daily multivitamin was also not significantly associated with total mortality (HR, 0.94; 95% CI, 0.88–1.02; P=0.13). The effect of a daily multivitamin on major cardiovascular events did not differ between men with or without a baseline history of CVD (P, interaction = 0.62).
A daily multivitamin did not reduce major cardiovascular events, MI, stroke, and CVD mortality after more than a decade of treatment and follow-up.
Despite uncertainty regarding its long-term health benefits, many US adults take vitamin supplements1 to prevent chronic diseases2 or for general health and well-being.3 Since multivitamins are the most common supplement taken by US adults4,5 there are broad public health implications regarding their everyday use. Individuals who feel they are deriving benefits from supplements may be less likely to engage in other preventive health behaviors, and chronic daily supplement use poses a financial burden with annual vitamin supplement sales in the billons of US dollars.6 A daily multivitamin, with its combination of essential vitamins and minerals that meet minimum RDA levels, may replicate broader, healthier dietary and food patterns identified in epidemiologic studies for CVD prevention.7,8 Observational studies of multivitamin use and cardiovascular incidence and mortality are limited and inconsistent.9–16
Randomized clinical trials have tested the effect of individual vitamins and minerals - including beta-carotene,17–19 vitamin E,19–22 vitamin C,19,22 selenium,23 and B vitamins,24,25 among others - with the vast majority showing no effect on CVD endpoints. Only a few large-scale trials have tested smaller combinations of vitamins or minerals, typically selected from those already tested individually and equivocally,26–28 for which there has been a lack of effect. There have been no large-scale trials of a multivitamin in CVD prevention. Accordingly, an NIH conference panel29 and the 2010 Dietary Guidelines concluded that there is no evidence to support a daily multivitamin in disease prevention, including CVD.
The Physicians' Health Study II (PHS II) is the only large-scale trial testing the effects of long-term use of a common multivitamin on the risk of major cardiovascular events and cancer among 14,641 male physicians. In this paper, we present the findings for multivitamin use on major cardiovascular events. Results for cancer, eye disease, and cognitive decline are being published separately.
The Physicians' Health Study II (PHS II) was a randomized, double-blind, placebo-controlled, 2×2×2×2 factorial trial evaluating the balance of risks and benefits of a multivitamin (Centrum Silver or its placebo daily; Pfizer (formerly Wyeth, American Home Products, and Lederle)), vitamin E, vitamin C, and beta-carotene in the prevention of CVD, cancer, eye disease, and cognitive decline among 14,641 male physicians initially aged ≥50 years.31 The beta-carotene component ended as scheduled in March 2003, and the vitamin E and C components ended as scheduled in 2007 with a lack of effect reported for CVD22 and cancer.32
As detailed previously,22,31,32 PHS II recruitment, enrollment, and randomization occurred in two phases (Figure 1). In Phase 1, starting in July 1997, we invited 18,763 living participants from PHS I, a randomized trial of low-dose aspirin33 and beta-carotene17 among 22,071 male physicians, to participate in PHS II. Men were ineligible if they reported a history of cirrhosis, active liver disease, were taking anticoagulants, or reported a serious illness that might preclude participation. Men also must have been willing to forego current use of multivitamins or individual supplements containing more than 100% of the RDA of vitamin E, vitamin C, beta-carotene, or vitamin A. Men with a history of myocardial infarction (MI), stroke, or cancer remained eligible. We randomized 7,641 (41%) willing and eligible PHS I participants into PHS II.
Phase 2 began in July 1999 with invitational letters and baseline questionnaires sent to 254,597 additional US male physicians aged ≥50 years identified from a list from the American Medical Association that excluded PHS I participants. By July 2001, 42,165 (16.6%) men completed the baseline PHS II questionnaire, of whom 11,128 (26.4%) were willing and eligible based upon the same eligibility criteria as PHS I participants. Of 11,128 physicians who entered a run-in phase, 7,000 (63%) were compliant with their pills and were randomized into PHS II.
A total of 14,641 men were randomized into PHS II in blocks of 16 and stratified by age, prior diagnosis of cancer, prior diagnosis of CVD, and, for 7,641 PHS I participants, their original beta-carotene treatment assignment. There were 754 (5.1%) men with a history of MI or stroke before randomization. All participants provided written informed consent, and the Institutional Review Board at Brigham and Women's Hospital approved the research protocol.
Every six months for the first year, then annually thereafter PHS II participants were sent monthly calendar packs containing a multivitamin or placebo. Annual mailed questionnaires asked about compliance, adverse events, endpoints, and risk factors. Blinded treatment and follow-up continued through June 1, 2011, the scheduled end of the PHS II multivitamin component. Data analyses include follow-up and validation of reported endpoints through August 2012. Morbidity and mortality follow-up in PHS II were extremely high, at 98.2% and 99.9%, respectively. In addition, morbidity and mortality follow-up as a percentage of person-time each exceeded 99.9%. Adherence with the multivitamin component was defined from participant self-reports as taking at least two-thirds of the pills, which has been shown to be very reliable in physicians.34
For the multivitamin component, the primary endpoint was major cardiovascular events (including nonfatal MI, nonfatal stroke, and cardiovascular mortality). Pre-specified secondary endpoints included in this report include total MI and total stroke. Other endpoints considered in these analyses included fatal and nonfatal MI and stroke, cardiovascular death, ischemic and hemorrhagic stroke, and total mortality.
For each of the above endpoints reported by participants, we requested permission from the participant to examine all relevant medical records. Upon receipt of consent, medical records were requested and reviewed by an Endpoints Committee of physicians blinded to randomized treatment assignment. We were unable to obtain adequate medical records for <5% of the endpoints. The diagnosis of MI was confirmed by evidence of symptoms in the presence of either diagnostic elevations of cardiac enzymes or diagnostic changes on electrocardiograms. For fatal events, the diagnosis of MI was also accepted based upon autopsy findings.33 We confirmed diagnoses of stroke defined as a typical neurologic deficit of sudden or rapid onset and vascular origin, lasting >24 hours. Stroke was classified according to National Survey of Stroke criteria into ischemic, hemorrhagic and unknown subtype,35 with high interobserver agreement.36 Participant deaths were usually reported by family members or postal authorities. Following a report of a participant death, death certificates and/or autopsy reports were obtained. Total mortality was confirmed by the Endpoints Committee or by death certificate. CVD mortality was additionally documented by convincing evidence of a cardiovascular mechanism from all available sources. For men with unknown vital status, we used web and National Death Index searches to identify deaths. Only confirmed endpoints of MI, stroke, and CVD death were included in this analysis. We also collected data on participant self-reports of congestive heart failure, angina pectoris, and revascularization (including coronary artery bypass graft and percutaneous coronary intervention) for inclusion in our analyses.
All primary analyses were based upon the intention-to-treat principle, in which all 14,641 randomized PHS II participants were classified according to their randomized multivitamin treatment assignment and followed until the occurrence of major cardiovascular events, death, loss to follow-up, or the end of the multivitamin component of PHS II on June 1, 2011. We used SAS version 9.2 (SAS Institute Inc.) and S-Plus (Insightful Corp.), with statistical significance set at P<0.05 using 2-sided tests. The PHS II was estimated to have 80% power to detect a 12% reduction in the primary endpoint of major cardiovascular events.
We initially compared baseline characteristics by multivitamin treatment assignment to ensure randomization equally distributed baseline characteristics by active versus placebo groups. As done in previous PHS II trial analyses,22,32 Cox proportional hazards models estimated the HRs and 95% confidence intervals (CIs) comparing event rates in the multivitamin and placebo groups. For each pre-specified endpoint, we stratified on the presence of CVD at randomization and adjusted for PHS II study design variables, including age (in years), PHS cohort (original PHS I participant, new PHS II participant), and randomized vitamin E, vitamin C, and beta-carotene assignments. For analyses of total major cardiovascular events, all new events were included, regardless of whether the participant had a baseline history of CVD. Analyses of individual cardiovascular endpoints did not censor men upon occurrence of another cardiovascular endpoint. For analyses of total and cardiovascular mortality, we included all 14,641 PHS II participants, and for total mortality we additionally stratified by history of cancer at randomization.
We tested the proportional hazards assumptions by including an interaction term for multivitamin treatment with the logarithm of time, and this assumption was not violated for major cardiovascular events, total MI, and total stroke (each P>0.05). Cumulative incidence curves compared the overall effect of the multivitamin component on major cardiovascular events, total MI, and total stroke using a crude log-rank test. We investigated the effect of compliance with the multivitamin intervention on our primary results through sensitivity analyses using censoring and stratification.
We then conducted additional exploratory analyses on the effect of the multivitamin intervention on major cardiovascular events, total MI, and total stroke after excluding the first two or five years of follow-up to explore a possible early or late benefit associated with long-term multivitamin use. We also conducted subgroup analyses stratified by major risk factors, parental history of MI <60 years, and selected coronary biomarkers and dietary factors available in a subgroup of PHS II participants. Finally, we evaluated the effect of a daily multivitamin within the pre-specified subgroups of 754 men with and 13,887 men without a baseline history of CVD. Effect modification was assessed by using interaction terms between subgroup indicators and randomized multivitamin treatment assignment.
We randomized 14,641 men into PHS II with a mean (±SD) age of 64.3 (±9.2) years. Factors measured at baseline were similar between the multivitamin and placebo groups (Table 1). Among coronary risk factors, there was a low proportion of current smokers (3.6%) and a relatively high proportion of men who exercised ≥1 time/wk (59.9%), which was countered with 42.0%, 35.4% and 6.2% of men reporting a history of hypertension, high cholesterol, and diabetes, respectively. Baseline aspirin use was high (76.3%) in this population of physicians, in part reflective of their previous participation and results of the PHS I trial testing aspirin and CVD.33 There were 754 (5.1%) and 1,312 (9.0%) men with a baseline history of CVD and cancer, respectively.
Mean follow-up of PHS II participants was 11.2 years (median [interquartile range], 11.2 [10.7–13.3] years; maximum, 13.8 years), totaling 164,320 person-years. For active multivitamin and its placebo, adherence at 4 years was 76.8% and 77.1%, respectively (P=0.71); at 8 years, 72.3% and 70.7% (P=0.15); and at the end of follow-up, 67.5% and 67.1% (P=0.70). There were small differences between the active and placebo groups comparing the avoidance of individual non-trial multivitamin use (<30 days/year) at 4 years (86.7% and 85.4%, respectively; P=0.03) and 8 years (78.5% and 75.8%, P=0.01) follow-up, but not by the end of multivitamin follow-up (81.0% and 80.3%; P=0.35). During multivitamin treatment, we confirmed that 1,732 men had major cardiovascular events, including 652 cases (first events) of MI, 643 cases of stroke (527 and 94 cases of ischemic and hemorrhagic stroke, respectively), and 829 had cardiovascular death, with some men experiencing multiple events. A total of 2,757 (18.8%) men died during follow-up.
The rates of major cardiovascular events were 11.0 and 10.8 per 1,000 person-years in the active and placebo multivitamin groups, respectively. Men taking an active daily multivitamin experienced no benefit on the primary endpoint of major cardiovascular events (HR, 1.01; 95% CI, 0.91–1.10; P=0.91) (Table 2), with similar cumulative incidence curves (crude log-rank P=0.69) (Figure 2). There was a similar lack of significant benefit on the secondary endpoints of total MI (HR, 0.93; 95% CI, 0.80–1.09; P=0.39) and total stroke (HR, 1.06; 95% CI, 0.91–1.23; P=0.48) compared with men taking the placebo multivitamin. This lack of effect is illustrated in the corresponding cumulative incidence curves (both crude log-rank P>0.05) (Figure 2). In secondary analyses, there were fewer deaths among multivitamins users, but significance was marginal especially given the number of analyses conducted. (HR, 0.61; 95% CI, 0.38–1.00; P=0.048). Among stroke subtypes, a daily multivitamin had no effect on either ischemic stroke (HR, 1.10; 95% CI, 0.92–1.30; P=0.29) or hemorrhagic stroke (HR, 1.08; 95% CI, 0.72–1.63; P=0.69). We found no significant effect of a daily multivitamin on rates of congestive heart failure (HR, 0.95; 95% CI, 0.83–1.09; P=0.47), angina (HR, 1.00; 95% CI, 0.91–1.09; P=0.96), and coronary revascularization (HR, 1.03; 95% CI, 0.94–1.13; P=0.50). Daily multivitamin was not significantly associated with cardiovascular mortality (HR, 0.95; 95% CI, 0.83–1.09; P=0.47). There were fewer deaths among multivitamin users (HR, 0.94; 95% CI, 0.88–1.02; P=0.13), but this was not statistically significant.
In secondary analyses, exclusion of the first two or five years of follow-up did not alter the results for major cardiovascular events, total MI, or total stroke. Analyses adjusting for compliance either during follow-up or averaged over the whole trial, or adjusting for drop-ins, did not materially change the effect of the multivitamin on risk of major cardiovascular events.
In subgroup analyses, we examined whether baseline clinical, lifestyle, familial, biochemical, and dietary risk factors for CVD, along with the other randomized PHS II interventions, modified the effect of a daily multivitamin on major cardiovascular events (Table 3). There was a suggestion of a differential effect across age groups (P, interaction = 0.041), with possible differences among men aged 50–59 years (HR, 1.27; 95% CI, 0.99–1.63; P=0.06) and men aged ≥70 years (HR, 0.91; 95% CI, 0.81–1.03; P=0.14). We found no other evidence of effect modification by baseline risk factors on major cardiovascular events (all P, interaction > 0.05). There were also no multiplicative or subadditive interactions of the multivitamin component with randomized vitamin C, vitamin E, or beta-carotene treatment in PHS II (all P, interaction > 0.05).
We found no significant interaction by baseline CVD history status (P, interaction = 0.62) for primary (HR, 1.02) versus secondary (HR, 0.96) prevention (Table 4). The cumulative incidence curves did not differ for primary (crude log-rank P=0.71) or secondary (crude log-rank P=0.94) prevention during up to 14 years of treatment and follow-up (Figure 3). The apparent lower rate of MI death among multivitamin users persisted (HR, 0.56; 95% CI, 0.33–0.95; P=0.032), whereas power was limited with only 9 cases of MI death among those with baseline CVD (P, interaction = 0.31). The effect of a daily multivitamin on total MI, total stroke, and other cardiovascular endpoints did not differ between those with and without baseline CVD (all P, interaction > 0.05).
Besides the primary and secondary endpoints, we assessed several potential side effects of daily multivitamin use, and found no significant effects on gastrointestinal tract symptoms (peptic ulcer, constipation, diarrhea, gastritis, and nausea), fatigue, drowsiness, skin discoloration, and migraine (all P > 0.05). Those taking the active versus placebo multivitamin use were more likely to have skin rashes (2,111 and 1,973 men in corresponding active and placebo multivitamin groups; HR, 1.08; 95% CI, 1.01–1.15; P=0.016). In addition, there were inconsistent findings for daily multivitamin use on minor bleeding, suggesting the role of chance. There was a reduction in hematuria (998 and 1,105 men in corresponding active and placebo multivitamin groups; HR, 0.89; 95% CI, 0.81–0.97; P=0.006), an increase in epistaxis (1,216 and 1,106 men in corresponding active and placebo multivitamin groups; HR, 1.11; 95% CI, 1.02–1.20; P=0.016), and no effect on easy bruising/other bleeding (1,927 and 1,902 men in corresponding active and placebo multivitamin groups; HR, 1.02; 95% CI, 0.96–1.08; P=0.59).
The Physicians' Health Study II represents the only large-scale, randomized, double-blind, placebo-controlled trial testing the long-term effects of a commonly available multivitamin in the prevention of chronic disease. We found that after more than a decade of daily multivitamin use among middle-aged and older men, daily multivitamin use did not reduce the primary endpoint of major cardiovascular events. Multivitamin use also did not reduce the risk of total MI, total, ischemic, or hemorrhagic stroke, cardiovascular death, or other cardiovascular endpoints including congestive heart failure, angina, or coronary revascularization. A borderline significant 39% reduction in fatal MI may have been due to chance. These findings on CVD and the decision to take a multivitamin should be put in the context of initial nutritional status and other outcomes to be considered in this trial.
The lack of an effect of a daily multivitamin on CVD appears consistent with what is known to date. Basic research indicates several mechanisms by which specific micronutrients contained in multivitamins may prevent CVD37,38 through modifications in platelet activity,39 reductions in thrombotic potential,40 and modifications in vascular reactivity.41 The consistent observation that people consuming greater amounts of fruits and vegetables tend to have lower rates of coronary heart disease (CHD)42 and stroke43 supports the idea that combinations of vitamins at moderate dose may offer CVD protection.
Observational data examining multivitamin use and CVD are sparse and inconsistent. Among 1,063,023 US adults from the Cancer Prevention Study II, men without CVD had an age-adjusted relative risk (RR) of ischemic heart disease death for multivitamin use of 0.91 (P≤0.001) attenuated upon multivariate adjustment;10 similar results were noted for women. In 80,082 Nurses' Health Study participants, multivitamin use was associated with a significant reduction in coronary heart disease (CHD) incidence (RR, 0.76; 95% CI, 0.65–0.90) after 14 years,9 a result further confirmed with additional follow-up.12 In a Swedish population-based case-control study in adults aged 45 to 70 years, the multivariate odds ratio (OR) of MI comparing regular users versus nonusers of multivitamins was 0.79 (95% CI, 0.63–0.98) among 2,053 men and 0.66 (95% CI, 0.48–0.91) among 928 women.13 In contrast, in the PHS I enrollment cohort of 83,936 initially healthy male physicians, there was no association between baseline multivitamin use and either CVD or CHD mortality.11 Among 161,808 WHI participants, of whom 41.5% took a multivitamin, there was no association between multivitamin use and the risk of CVD, MI, or stroke after a median of 8 years follow-up.14 Finally, there was also no association between multivitamin use and cardiovascular mortality in 182,099 men and women from the Multiethnic Cohort Study after a mean follow-up of 11 years.16
Several large trials of single agents or combinations of vitamins and minerals, generally at doses well above RDAs and that contained in the PHS II multivitamin, have demonstrated no effect on CVD.17,18,20,44 Primary prevention trials that have examined smaller combinations of vitamins and minerals, including the Linxian Chinese Cancer Prevention Trial26 and SU.VI.MAX,28 as well as secondary prevention trials such as the Heart Protection Study,27 found no effect on CVD. Other randomized trials have tested combinations of B vitamins with folic acid at high doses, particularly in the secondary prevention of CVD, but have not found any protective effect.45 Moreover, the Women's Health Initiative Calcium and Vitamin D trial, testing 400 IU/day vitamin D3 plus 1000 mg/day calcium, found no effect on CVD.46
Baseline nutritional status among our physician participants remains a critical consideration in the interpretation of our findings. PHS II participants likely represent, on average, a well-nourished population who already have adequate or optimum intake levels of nutrients, for which supplementation may offer no additional benefit.47 However, the requirement for PHS II participants to avoid personal use of multivitamin supplements also lowered their in-trial intake of essential vitamins and minerals. Additional studies are needed to understand how the range of baseline nutritional status among PHS II participants and other populations may modify the effect of a daily multivitamin on cardiovascular endpoints. Further, we have an arsenal of behavioral (e.g. exercise, weight loss) and pharmacological interventions (e.g. lipid-lowering therapies) that effectively lower CVD risk. This may make it difficult for vitamin supplements such as a multivitamin to meaningfully contribute toward risk reduction.
Several unique strengths of this trial include more than a decade of treatment and follow-up, high statistical power for our primary endpoint of major cardiovascular events, consistently good adherence in taking a daily multivitamin, and the inclusion of physician participants in providing high-quality reporting of health information. We are unaware of any other long-term clinical trials that have tested a multivitamin in the prevention of CVD and other chronic diseases, highlighting the importance of trials like PHS II to test the efficacy of supplements and assess potential causality across a range of clinically relevant outcomes. Finally, we selected a commonly used multivitamin formulation, Centrum Silver, when we initiated PHS II to increase the generalizability of our findings.
There are also important potential limitations to be considered. We relied upon a specific, constant formulation of a Centrum Silver (eTable 1), which is one of many multivitamin formulations. There was an observed reduction in total cancer found for the PHS II multivitamin48 suggesting, however, that the formulation used may be adequate for cancer, but not for CVD. This highlights the need to understand how essential vitamins and minerals may differentially interact and influence cardiovascular and cancer mechanisms, even at usual levels of vitamin and mineral intake. Though PHS II included more than a decade of treatment, an even longer duration of multivitamin use may be required to derive any cardiovascular benefits. Existing epidemiologic data can provide insight on this concept, while PHS II remains the only trial of its kind for which extended follow-up of CVD endpoints can provide important longer-term mechanistic perspectives.
PHS II may also have limited generalizability, since our study population was confined to middle-aged and older, predominantly Caucasian male physicians. Despite some multivitamin non-compliance and drop-ins during PHS II, compliance- and drop-in-adjusted analyses reiterated a lack of effect of multivitamin use on major cardiovascular events. As with any trial, chance may be important when multiple hypotheses are tested, thus cautious interpretation of secondary analyses is warranted. Finally, long-term multivitamin use may be more effective when initiated earlier in life to counter the initiation and progression of atherosclerosis that often begins at an earlier age.
In this randomized trial after a mean of 11.2 years of treatment and follow-up in 14,641 men, daily multivitamin supplementation did not reduce the risk of major cardiovascular events. These data do not support multivitamin use to prevent CVD, demonstrating the importance of long-term clinical trials of commonly used nutritional supplements. Whether or not to take a daily multivitamin requires consideration of an individual's nutritional status, since the main reason is to prevent vitamin and mineral deficiency, plus consideration of other potential effects, including a modest reduction in cancer48 and other important outcomes in PHS II that will be reported separately.
Supported by grants CA 097193, CA 34944, CA 40360, HL 26490, and HL 34595 from the National Institutes of Health (Bethesda, MD), and an investigator-initiated grant from BASF Corporation (Florham Park, NJ). Study agents and packaging were provided by BASF Corporation and Pfizer (formerly Wyeth, American Home Products, and Lederle) (New York, NY), and study packaging was provided by DSM Nutritional Products, Inc. (formerly Roche Vitamins) (Parsippany, NJ).
Trial Registration: http://www.clinicaltrials.gov identifier: NCT00270647
Study concept and design: Sesso, Christen, Manson, Glynn, Buring, Gaziano.
Acquisition of data: Sesso, Christen, Bubes, Smith, MacFadyen, Schvartz, Manson, Glynn, Buring, Gaziano.
Analysis and interpretation of data: Sesso, Christen, Bubes, Manson, Glynn, Buring, Gaziano.
Drafting of the manuscript: Sesso, Gaziano.
Critical revision of the manuscript for important intellectual content: Sesso, Christen, Bubes, Smith, MacFadyen, Schvartz, Manson, Glynn, Buring, Gaziano.
Statistical analysis: Sesso, Bubes, Glynn, Gaziano.
Obtained funding: Sesso, Buring, Gaziano.
Administrative, technical, or material support: Sesso, Bubes, Smith, MacFadyen, Schvartz, Manson, Glynn, Gaziano.
Study supervision: Sesso, Bubes, Smith, MacFadyen, Glynn, Gaziano.
Dr. Sesso reported receiving investigator-initiated research funding from the National Institutes of Health, the Tomato Products Wellness Council, and Cambridge Theranostics, Ltd.
Dr. Christen reported receiving research funding support from the National Institutes of Health, Harvard University (Clinical Nutrition Research Center), and DSM Nutritional Products Inc. (formerly Roche Vitamins).
Dr. Manson reported receiving investigator-initiated research funding from the National Institutes of Health, and assistance with study pills and packaging from BASF and Cognis Corporations for the Women's Antioxidant and Folic Acid Cardiovascular Study and from Pronova BioPharma and Pharmavite for the VITamin D and OmegA-3 TriaL, and funding from the non-profit Aurora Foundation.
Dr. Glynn reported receiving investigator-initiated research funding from the National Institutes of Health, Bristol-Meyers Squibb, AstraZeneca, and Novartis, and signed a consulting agreement with Merck to give an invited talk.
Dr. Buring reported receiving investigator-initiated research funding from the National Institutes of Health, and assistance with study pills and packaging from Natural Source Vitamin E Association and Bayer Healthcare for the Women's Health Study.
Dr. Gaziano reported receiving investigator-initiated research funding from the National Institutes of Health the Veterans Administration, and the BASF Corporation to assist in the establishment of this trial cohort, assistance with study agents and packaging from BASF Corporation and Pfizer (formerly Wyeth, American Home Products, and Lederle), and assistance with study packaging provided by DSM Nutritional Products, Inc. (formerly Roche Vitamins).
Funding/Support: Supported by grants CA 097193, CA 34944, CA 40360, HL 26490, and HL 34595 from the National Institutes of Health (Bethesda, MD), and an investigator-initiated grant from BASF Corporation (Florham Park, NJ). Study agents and packaging were provided by BASF Corporation and Pfizer (formerly Wyeth, American Home Products, and Lederle) (New York, NY), and study packaging was provided by DSM Nutritional Products, Inc. (formerly Roche Vitamins) (Parsippany, NJ).
Role of the Sponsors: NIH, BASF, Pfizer, and DSM Nutritional Products Inc had no role in the study design; conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Author Contributions: Drs. Sesso and Gaziano had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analyses. Drs. Sesso, Bubes, Glynn, and Gaziano performed and are responsible for the statistical analyses for this article.
Disclosures:No other authors reported financial disclosures.
Data and Safety Monitoring Board: Voting members over the course of the PHS II trial included Lawrence Cohen, Rory Collins, Theodore Colton, I. Craig Henderson, Andrea LaCroix, Ross Prentice, and Nanette Wenger (chair); ex-officio members included Mary Francis Cotch, Jeffrey Cutler, Frederick Ferris, Jerome Fleg, Peter Greenwald, Natalie Kurinij, Howard Parnes, Marjorie Perloff, Eleanor Schron, and Alan Zonderman.
Disclaimer: Dr Gaziano, a contributing editor for JAMA, was not involved in the editorial review of or decision to publish this article.
Additional Contributions: We are deeply indebted to the 14,641 physician participants for their long-standing dedication and conscientious collaboration. We also acknowledge the long-term contributions of Charles Hennekens, MD, DrPH, Florida Atlantic University, to the Physicians' Health Study, and the exemplary contributions of the staff of the Physicians' Health Study at Brigham and Women's Hospital, under the leadership of Joanne Smith: Charlene Belanger, Eileen Bowes, Kenneth Breen, Mary Breen, Mary G. Breen, Jose Carrion, Shamikhah Curry, Colleen Evans, Ivan Fitchorov, Natalya Gomelskaya, Cindy Guo, Delia Guo, Jasmah Hanna, Beth Holman, Andrea Hrbek, Gregory Kotler, Tony Laurinaitis, Matthew Lyle, Hannah Mandel, Chandra McCarthy, Geneva McNair, Annie Murray, Leslie Power, Philomena Quinn, Harriet Samuelson, Fred Schwerin, Mickie Sheehey, Sara Tower, Martin Van Denburgh, Diana Walrond, Phyllis Johnson Wojciechowski, and Angela Zhang. Finally, we are deeply grateful for the efforts of the Physicians' Health Study Endpoints Committee, including Samuel Goldhaber, Carlos Kase, Meir Stampfer, and James Taylor, over the course of Physicians' Health Study II. Each named individual was compensated for his/her contribution as part of the grant support.